Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Remimazolam Tosilate
The First People's Hospital of Lianyungang
Frailty
1 trial -
Remimazolam besylate
The First People's Hospital of Lianyungang
Remimazolam
1 trial -
Respiratory monitoring
The First People's Hospital of Lianyungang
Post-Op Complication
1 trial -
Rifaximin
The First People's Hospital of Lianyungang
Bacterial Overgrowth Syndrome Small Bowel
1 trial -
Ringer's solution acetate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Cholecystolithiasis and Thyroid Nodule
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Peripheral T-Cell Lymphoma, Not Otherwise Specified
1 trial -
Rituximab
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenic Purpura
1 trial -
Rituximab, Methotrexate, and Thiotepa (R-MT) Induction Followed by Etoposide and Cytarabine (EA) Consolidation
The First People's Hospital of Lianyungang
Primary Central Nervous System Lymphoma (PCNSL)
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Liver Cirrhosis
1 trial -
Rivaroxaban
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Ventricular Mural Thrombosis
1 trial -
Romiplostim N01
The First People's Hospital of Lianyungang
Primacy Immune Thrombocytopenia
1 trial -
Ropivacaine
Hospital Authority, Hong Kong
Femoral Fracture
1 trial -
Ropivacaine
Hospital Authority, Hong Kong
Liver Diseases
1 trial -
Ropivacaine
The First People's Hospital of Lianyungang
Surgery
1 trial -
Ropivacaine Hydrochloride 10 MG/ML [Naropin]
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Colorectal Cancer
1 trial -
Routine Medication
The First People's Hospital of Lianyungang
Generalized Anxiety Disorder
1 trial -
Ruxolitinib+Calcineurin inhibitor+Methotrexate
The First People's Hospital of Lianyungang
Graft Versus Host Disease
1 trial -
S-ketamine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Anesthesia
1 trial -
S-ketamine
The First People's Hospital of Lianyungang
Opioid Use, Unspecified
1 trial -
S-ketamine
Nanjing Zenshine Pharmaceuticals
Opioid Use, Unspecified
1 trial -
SA58 Nasal Spray
Sinovac Research and Development Co.,
COVID-19
2 trials -
SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
The First People's Hospital of Lianyungang
SARS-CoV-2
1 trial -
SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
The First People's Hospital of Lianyungang
SARS-CoV-2
1 trial -
SBRT
Hospital Authority, Hong Kong
Spine Metastases
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources